Chris Ryan
Articles
Frontline Liposomal Irinotecan/NALIRIFOX Confers OS Benefit in Metastatic Pancreatic Ductal Adenocarcinoma
January 25, 2023
Article
The median overall survival with frontline liposomal irinotecan/NALIRIFOX was 11.1 months vs 9.2 months with nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
Moxetumomab Pasudotox Will Be Removed From US Market for Hairy Cell Leukemia
January 17, 2023
Article
Moxetumomab pasudotox-tdfk, a treatment for patients with relapsed/refractory hairy cell leukemia, will be permanently discontinued.
RP1 Plus Nivolumab Generates Activity in Pretreated Cutaneous Melanoma
December 23, 2022
Article
A combination of vusolimogene oderparepvec and nivolumab elicited early clinical activity in patients with cutaneous melanoma whose disease did not response to anti-PD-1 therapy.
Dostarlimab Improves Progression-Free Survival in Advanced or Recurrent Endometrial Cancer
December 09, 2022
Article
Dostarlimab plus standard-of-care chemotherapy, followed by dostarlimab alone, met a predetermined progression-free survival end point in the phase 3 RUBY trial.
Nivolumab/Ipilimumab Induces Stark Overall Response Rate in Checkpoint Inhibitor–Naïve Merkel Cell Carcinoma
December 04, 2022
Article
All 24 patients with Merkel cell carcinoma who received nivolumab plus ipilimumab responded to treatment, and 41% achieved complete responses.
Pembrolizumab Combination Delivers Overall Survival Benefit in HER2-Negative Gastric/GEJ Adenocarcinoma
November 29, 2022
Article
Pembrolizumab plus physician’s choice of chemotherapy bested placebo plus chemotherapy in improving overall survival rates in patients with HER2-negative gastric cancer or gastroesophageal junction adenocarcinoma, regardless of PD-L1 expression.
Belantamab Mafodotin Will No Longer Be Available For Multiple Myeloma
November 28, 2022
Article
In light of findings from the phase 3 DREAMM-3 trial, manufacturers have elected to withdraw belantamab mafodotin-blmf from the United States market.
Camsirubicin Demonstrates Efficacy, Tolerability in Advanced Soft Tissue Sarcoma
November 26, 2022
Article
Combining the doxorubicin analogue camsirubicin with pegfilgrastim yielded encouraging clinical activity in patients with advanced soft tissue sarcoma.
Evolving Immunotherapy Data Shed Light on Best Practices in Metastatic Melanoma
November 13, 2022
Article
During the 40th Annual Chemotherapy Foundation Symposium, Jeffrey S. Weber, MD, PhD, discussesed best sequencing practices in metastatic melanoma.
Sacituzumab Govitecan Receives Priority Review Status for HR+/HER2- Metastatic Breast Cancer
October 14, 2022
Article
Following promising efficacy data from the phase 3 TROPiCS-02 trial, the FDA has granted sacituzumab govitecan priority review status on the indication of HR+/HER2 metastatic breast cancer.